Matthew Box

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Peter Ballard, James Yates, Zhenfan Yang et al. · Clinical Cancer Research · 2016 · 719 citations

Medicine, Oncology, Pharmacology +17

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 602 citations · Full text

Medicine, Oncology, Pharmacology +15

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

Richard A. Ward, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2013 · 261 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Late Glacial to Holocene benthic foraminifera in the Marmara Sea: implications for Black Sea–Mediterranean Sea connections following the last deglaciation

Michael A. Kaminski, A.E. Aksu, Matthew Box et al. · Marine Geology · 2002 · 128 citations

Natural Sciences, Marine Sciences, Oceanography +16

Discovery of Pyrazolo[1,5-<i>a</i>]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors

William McCoull, Roman Abrams, Erica Anderson et al. · Journal of Medicinal Chemistry · 2017 · 78 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17